FDA denies Ocaliva full approval, but Intercept hopes to keep drug on market

The FDA rejected the full approval submission for Intercept Pharmaceuticals and Alfasigma’s primary biliary cholangitis treatment Ocaliva after safety concerns dogged the product, casting its future into doubt. While Intercept